内镜下球囊扩张与支架置入治疗原发性硬化性胆管炎主导性狭窄的系统评价与荟萃分析
该系统评价与荟萃分析比较内镜下球囊扩张(EBD)与支架置入治疗原发性硬化性胆管炎(PSC)主导性狭窄的疗效与安全性。结果显示EBD临床疗效更优且治疗次数更少,支架置入降低胆红素更明显但不良事件(尤其胆管炎)更多,提示支架可能用于晚期或EBD失败病例。
要点
- EBD临床疗效优于支架置入,且人均干预次数更少。
- 支架置入降低胆红素更明显,但不良事件和胆管炎发生率更高。
- 支架置入可能提示更晚期疾病,用于严重狭窄或EBD失败者。
核心结论
- EBD临床疗效显著优于支架置入,且治疗次数更少。
- 支架置入降低血清胆红素幅度大于EBD,可能用于晚期PSC伴严重狭窄或EBD失败者。
研究设计与样本
- 系统评价与荟萃分析,检索多个数据库,比较EBD与支架置入治疗PSC主导性狭窄的疗效与安全性。
主要发现
- 人均干预次数:EBD为2.7±0.39,支架置入为6.5±0.01(SD 4.55±1.3 [1.48-6.6];P=.00)。
- 临床疗效:EBD为85.5%(95%CI 15.3-99.5;I2=54%),支架置入为84.9%(95%CI 56.6-96.1;I2=73%);RR 1.01(95%CI 0.89-1.14;I2=72%;P=.02)。
- 胆红素平均变化百分比:EBD组14.95%,支架置入组42.52%。
- 不良事件:支架置入44.5%(95%CI 23.3%-67.9%;I2=63%),EBD 15.0%(95%CI 8.5-15.0;I2=51%);RR 0.29(95%CI 0.14-0.61;P=.10)。
- 胆管炎:EBD 3.2%(95%CI 1.9%-5.4%;I2=0%),支架置入16.8%(95%CI 10.4%-25.9%;I2=0%);RR 0.24(95%CI 0.13-0.43;P=.65)。
关键数值与推荐
- 胰腺炎发生率:EBD 6.7%(95%CI 3.7-11.7%;I2=39%),支架置入10.1%(95%CI 6.5%-15.4%;I2=41%);RR 0.74(95%CI 0.40-1.35;P=.20)。
- 穿孔率:EBD 3.8%(95%CI 1.8%-7.9%;I2=0%),支架置入3.3%(95%CI 0.8%-11.9%;I2=0%);RR 1.04(95%CI 0.36-2.99;P=.35)。
- 出血发生率:EBD 3.4%(95%CI 1.1%-10.2%;I2=0%),支架置入3.0%(95%CI 0.5%-17.4%;I2=0%);RR 0.57(95%CI 0.13-2.45;P=.88)。
临床怎么用
- 对PSC主导性狭窄可优先考虑EBD,以减少干预次数和不良事件。
- 支架置入可用于严重狭窄或EBD失败者,但需警惕胆管炎等不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Dominant strictures in primary sclerosing cholangitis (PSC) remain a matter of concern as the result of the cholestatic symptoms. Treatment options include endoscopic balloon dilation (EBD) or stent placement. The objective of our study was to compare the efficacy and safety between EBD and stent placement. METHODS: Multiple databases were searched for articles on EBD versus stent placement for treatment of dominant strictures in PSC. Preferred outcomes were subjected to systematic review and meta-analysis. RESULTS: The number of interventions per person was 2.7 ± 0.39 with EBD and 6.5 ± 0.01 with stent placement (SD 4.55 ± 1.3 [1.48-6.6); P = .00). Clinical efficacy was 85.5% (95% Cl, 15.3-99.5; I2 = 54%) with EBD and 84.9% (95% CI, 56.6-96.1; I2 = 73%) with stent placement; relative risk (RR), 1.01 (95% CI, 0.89-1.14; I2 = 72%; P = .02). The mean percentage change in bilirubin was 14.95% among the EBD group and 42.52% among the stent placement group. Adverse events were 44.5% (95% CI, 23.3%-67.9%; I2 = 63%) with stent placement compared to the EBD, 15.0% (95% CI, 8.5-15.0; I2 = 51%); RR, 0.29 (95% CI, 0.14-0.61; P = .10). Pancreatitis incidence was 6.7% (95% CI, 3.7-11.7%; I2 = 39%) and 10.1% (95% CI, 6.5%-15.4%; I2 = 41%) with EBD and stent placement respectively; RR, 0.74 (95% CI, 0.40-1.35; P = .20). EBD caused less cholangitis, 3.2% (95% CI, 1.9%-5.4%; I2 = 0%) compared with stent placement, 16.8 (95% CI, 10.4%-25.9%; I2 = 0%); RR, 0.24 (95% CI, 0.13-0.43; P = .65). Perforation rate was 3.8% (95% CI, 1.8%-7.9%; I2 = 0%) and 3.3% (95% CI, 0.8%-11.9%; I2 = 0%) with EBD and stent placement, respectively; RR, 1.04 (95% CI, 0.36-2.99; P = .35). Bleeding occurrence was 3.4% (95% CI, 1.1%-10.2%; I2 = 0%) with EBD and 3.0% (95% CI, 0.5%-17.4%; I2 = 0%) with stent placement; RR, 0.57 (95% CI, 0.13-2.45; P = .88). CONCLUSIONS: EBD demonstrated significantly better clinical efficacy with fewer treatment sessions. Stent placement reduces serum bilirubin more than EBD and is used in advanced PSC with severe strictures or EBD failure, potentially indicating more advanced disease.
引用
- Garg A, Moond V, Garg A, et al. Endoscopic balloon dilation versus stent placement in the management of dominant strictures in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointest Endosc. 2025. PMID: 40846243. doi:10.1016/j.gie.2025.08.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。